» Articles » PMID: 2909522

Location of the Antithrombin-binding Sequence in the Heparin Chain

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1989 Jan 5
PMID 2909522
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

The antithrombin-binding region of heparin is a pentasaccharide sequence with the predominant structure -GlcNAc(6-OSO3)-GlcA-GlcNSO3(3,6-di-OSO3)-Ido A(2-OSO3)- GlcNSO3(6-OSO3)-. By using the 3-O-sulfated glucosamine residue as a marker for the anti-thrombin-binding sequence, the location of this sequence within the heparin chain was investigated. Heparin with high affinity for antithrombin (HA-heparin) contains few N-acetyl groups located outside the antithrombin-binding region, and cleavage at such groups was therefore expected to be essentially restricted to this region. HA-heparin was cleaved at N-acetylated glucosamine units by partial deacetylation followed by treatment with nitrous acid at pH 3.9, and the resulting fragments with low affinity for anti-thrombin (LA-fragments) were recovered after affinity chromatography on immobilized antithrombin. The LA-fragments were further divided into subfractions of different molecular size by gel chromatography and were then analyzed with regard to the occurrence of the nonreducing terminal GlcA-GlcNSO3(3,6-di-OS-O3)- sequence. Such units were present in small, intermediate-sized as well as large fragments, suggesting that the antithrombin-binding regions were randomly distributed along the heparin chains. In another set of experiments, HA-heparin was subjected to limited, random depolymerization by nitrous acid (pH 1.5), and the resulting reducing terminal anhydromannose residues were labeled by treatment with NaB3H4. The molecular weight distributions of such labeled LA-fragments, determined by gel chromatography, again conformed to a random distribution of the antithrombin-binding sequence within the heparin chains. These results are in apparent disagreement with previous reports (Radoff, S., and Danishefsky, I. (1984) J. Biol. Chem. 259, 166-172; Rosenfeld, L., and Danishefsky, I. (1988) J. Biol. Chem. 263, 262-266) which suggest that the antithrombin-binding region is preferentially located at the nonreducing terminus of the heparin molecule.

Citing Articles

A French National Survey on Clotting Disorders in Mastocytosis.

Carvalhosa A, Aouba A, Damaj G, Canioni D, Brouzes C, Gyan E Medicine (Baltimore). 2015; 94(40):e1414.

PMID: 26447996 PMC: 4616764. DOI: 10.1097/MD.0000000000001414.


De novo synthesis of a narrow size distribution low-molecular-weight heparin.

Chandarajoti K, Xu Y, Sparkenbaugh E, Key N, Pawlinski R, Liu J Glycobiology. 2014; 24(5):476-86.

PMID: 24626379 PMC: 3976284. DOI: 10.1093/glycob/cwu016.


Therapeutically targeting protein-glycan interactions.

Rek A, KRENN E, Kungl A Br J Pharmacol. 2009; 157(5):686-94.

PMID: 19371327 PMC: 2721254. DOI: 10.1111/j.1476-5381.2009.00226.x.


Isolation and characterization of a heparin with low antithrombin activity from the body of Styela plicata (Chordata-Tunicata). Distinct effects on venous and arterial models of thrombosis.

Santos J, Mesquita J, Belmiro C, da Silveira C, Viskov C, Mourier P Thromb Res. 2007; 121(2):213-23.

PMID: 17482241 PMC: 2211419. DOI: 10.1016/j.thromres.2007.03.025.


Molecular-size-dependent variations in the proportions of chains with high binding affinities for antithrombin in rat skin heparin proteoglycans.

Horner A Biochem J. 1989; 262(3):953-8.

PMID: 2590178 PMC: 1133365. DOI: 10.1042/bj2620953.